Latest Earnings Results: Q3 '26
Estimated EPS
$0.00
Reported EPS
-$0.06
Surprise
-21528.57%
Estimated Rev
$68.56M
Reported Rev
$62.28M
Surprise
-9.16%
• Reported GAAP EPS of -$0.01 down -106.67% YoY • Reported revenue of $62.28M down -45.23% YoY • MiMedx expects 2026 net sales of $250 to $260M, fourth-quarter Adjusted EBITDA sequentially higher than the third quarter, and longer-term annual net sales growth in the low double-digits with adjusted EBITDA margin above 20%.
Bullish Takeaway
MiMedx recorded 9% year-over-year Surgical sales growth and nearly two-thirds of sales from Surgical, obtained a favorable AXIOFILL court ruling, and entered a $25M patent license agreement.
Bearish Takeaway
MiMedx faced a 71% year-over-year Wound sales decrease amid Medicare reimbursement changes, lower total sales and a net loss, plus FTC review and completion risks for Sanara.
Generated by Stocktwits using AI and company-reported earnings data for Q3 '26. This recap is intended to help readers understand the quarter quickly. Verify key figures in the linked source materials; the summary may contain errors and is not investment advice.
Historical Earnings
Quarterly
Annual
EPS
Revenue
| Fiscal Period | Estimated | Reported | Surprise | Result |
|---|---|---|---|---|
Q4 '26 | $0.02 | -- | -- | N/A |
Q3 '26 | $0.00 | -$0.06 | -21528.57% | MISSED |
Q2 '26 | -$0.05 | -$0.10 | -102.02% | MISSED |
Q1 '26 | -$0.03 | -$0.07 | -179.33% | MISSED |
Q4 '25 | $0.09 | $0.10 | 13.21% | BEAT |